drugset / Trial / NCT06453265

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

NCT06453265

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid Users.

Timeline

Start
2024-06-28
Primary completion
2024-11-06
Completion
2024-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cebranopadol Small molecule 600 ug Intranasal
Subject Cebranopadol Small molecule 800 ug Intranasal
Subject Cebranopadol Small molecule 1000 ug Intranasal
Comparator Oxycodone Other / unclassified 40 mg Intranasal

Indications